Tuesday, October 19, 2021

Pharma brand TV spending continues upswing in October, led by AbbVie and BMS


Pharma kept up the spending pace on TV in October. The top 10 brands nudged to $187 million total spending for the month, just ahead of September’s already robust $182 million.

That’s in spite of AbbVie Humira dropping its spending by $20 million. Though it held onto the top slot even after that spending cut, other brands stepped up—to the tune of 16 drugs that each spent more than $10 million for the month.

One brand new to the list was Novo Nordisk’s oral GLP-1 diabetes med Rybelsus with its first TV ad. The animated commercial—created in that format because of COVID-19 restrictions—features a bright, happy world and upbeat remake of the golden oldie song “You are My Sunshine.” The promo for the only oral GLP-1 drug targets patients who are newly diagnosed as well as patients looking for options in managing blood sugar and weight.

Free Webinar

Hindsight is so 2020 – Getting Ahead of CNS Trial Enrollment in a Rapidly Changing Clinical Landscape

The past six months have highlighted both existing and unexpected enrollment challenges, as sponsors, CROs, and sites have been pressed to evolve their recruitment strategies. Join us as Rho experts discuss their approach to adapting CNS trial enrollment to a rapidly changing clinical landscape. Register now.

Returning to the list in October were two antipsychotic drugs: Sunovion’s Latuda and Lundbeck and Otsuka’s Rexulti, both having launched new TV creative recently.

October marks another month of above-average spending for major pharma brands, tracking well above October 2019 spending of $165 million. The $187 million and $182 million spent in October and September 2020, respectively, continue the upswing from August’s $148 million and July’s $136 million.

1. Humira
Movement: Stayed same
What is it? AbbVie anti-inflammatory drug
Total estimated spending: $37.3 million (down from $57.7 million in September)
Number of spots: Five (Two for arthritis/psoriasis, three for ulcerative colitis/Crohn’s)
Biggest-ticket ad: “Body of Proof: Bicycling, Painting, Traveling” (est. $15.2 million)

2. Opdivo and Yervoy
Movement: Up from No. 3
What is it? Bristol Myers dual-immunotherapy cancer regimen
Total estimated spending: $22 million (down slightly from $22.7 million in September)
Number of spots: One
Biggest-ticket ad: “Combination Immunotherapy”

3. Rybelsus
Movement: Not on list last month
What is it? Novo Nordisk oral GLP-1 diabetes med
Total estimated spending: $21.9 million
Number of spots: One
Biggest-ticket ad: “Wake Up”

4. Skyrizi
Movement: Up from No. 6
What is it? AbbVie next-gen psoriasis treatment
Total estimated spending: $19.3 million (up from $11.3 million in September)
Number of spots: Four
Biggest-ticket ad: “Nothing is Everything” (est. $8.7 million)
 

5. Dupixent
Movement: Down from No. 2
What is it? Regeneron and Sanofi atopic dermatitis and asthma treatment
Total estimated spending: $16.4 million (down from $23.1 million in September)
Number of spots: Four (Two for atopic dermatitis, two for asthma)
Biggest-ticket ad: “Du More: Backyards and Rain” (est. $9 million)

6. Jardiance
Movement: Up from No. 8
What is it? Eli Lilly and Boehringer Ingelheim SGLT2 diabetes treatment
Total estimated spending: $15.4 million (up from $10.4 million in September)
Number of spots: Four
Biggest-ticket ad: “Community Garden” (est. $7.1 million)

7. Latuda
Movement: Not on list last month
What is it? Sunovion Pharmaceutical antipsychotic
Total estimated spending: $14.8 million
Number of spots: One
Biggest-ticket ad: “Art”

8.  Descovy
Movement: Down from No. 4
What is it? Gilead Sciences next-gen PrEP HIV drug
Total estimated spending: $13.5 million (down slightly from $13.7 million in September)
Number of spots: One
Biggest-ticket ad: “Prep Up”

9. Enbrel
Movement: Stayed same
What is it? Amgen’s TNF inhibitor for autoimmune diseases
Total estimated spending: $13.42 million (up from $10 million in September)
Number of spots: One
Biggest-ticket ad: “Erin & Margo”

10. Rexulti
Movement: Not on list last month
What is it? Otsuka and Lundbeck antipsychotic
Total estimated spending: $13.41 million
Number of spots: Two
Biggest-ticket ad: “These Days: Savings Card Benefit” (est. $7.9 million)
 

 



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...